

GLAXOSMITHKLINE PLC  
Form 6-K  
May 06, 2010

**FORM 6-K**

**SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549**

**Report of Foreign Issuer**

**Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934**

For period ending May 2010

**GlaxoSmithKline plc**  
(Name of registrant)

**980 Great West Road, Brentford, Middlesex, TW8 9GS**  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the

Securities Exchange Act of 1934.

Yes No x

--

**GlaxoSmithKline plc - Result of AGM**

GlaxoSmithKline (GSK) announces that at its Annual General Meeting today, all resolutions, including those electing and re-electing Board members, were passed by shareholders.

**GlaxoSmithKline Annual General Meeting Poll Results**

The following table shows the votes cast for each resolution:

	<b>Resolution</b>	<b>Total votes for*</b>	<b>%</b>	<b>Total votes against</b>	<b>%</b>	<b>Total votes cast</b>	<b>Votes withheld**</b>
1	Adoption of Financial Statements	3,598,418,923	98.82	43,141,670	1.18	3,641,560,593	5,644,370
2	Approval of the Remuneration Report	3,541,237,234	97.79	79,954,611	2.21	3,621,191,845	26,063,218
3	Re - Election of Dr Stephanie Burns	3,623,167,103	99.42	21,029,709	0.58	3,644,196,812	2,994,975
4	Re-election of Julian Heslop	3,614,453,830	99.40	21,794,823	0.60	3,636,248,653	10,945,821
5	Re-election of Sir Deryck Maughan	3,610,735,860	99.09	33,299,858	0.91	3,644,035,718	3,157,277
6	Re-election of Dr Daniel Podolsky	3,611,533,790	99.11	32,510,583	0.89	3,644,044,373	3,147,398
7	Re-election of Sir Robert Wilson	3,610,344,137	99.08	33,643,265	0.92	3,643,987,402	3,191,304
8	Re-appointment of Auditors	3,478,245,182	96.93	110,136,263	3.07	3,588,381,445	58,819,622
9	Remuneration of Auditors	3,564,492,662	98.45	56,106,748	1.55	3,620,599,410	26,616,714
10	To authorise the company to make donations to Political Organisations & incur Political Expenditure	3,542,930,783	97.36	95,902,968	2.64	3,638,833,751	8,442,409
11	Authority to allot shares	3,522,619,757	96.76	118,105,636	3.24	3,640,725,393	6,450,059
12	Disapplication of pre-emption rights***	3,605,918,864	99.14	31,425,913	0.86	3,637,344,777	9,718,766
13	Authority for the Company to purchase its own shares***	3,589,455,513	98.56	52,518,615	1.44	3,641,974,128	5,301,338
14	Exemption from statement of senior statutory auditor's name	3,624,009,356	99.65	12,682,719	0.35	3,636,692,075	10,468,603
15	Reduced notice of a general meeting other than an AGM***	3,367,402,408	92.71	264,960,544	7.29	3,632,362,952	14,848,460
16	Adoption of new Articles of Association***	3,576,628,823	99.44	20,021,827	0.56	3,596,650,650	50,514,919

**Notes:**

\* Includes discretionary votes.

\*\* A vote withheld is not a vote in law and is not counted in the calculation of the proportion of votes "For" or "Against" a resolution.

\*\*\* Indicates Special Resolutions requiring a 75% majority

The following table provides further relevant information:

	<b>GlaxoSmithKline's Tenth AGM (2010)</b>	<b>GlaxoSmithKline's Ninth AGM (2009)</b>
Issued share capital (excluding Treasury Shares)	5,192,489,588	5,188,385,638
Total votes cast and votes withheld lodged as a % of GSK's issued share capital (excluding Treasury Shares)	70.24%	73.50%
Total shareholder population	164,450	170,054
Total number of proxies lodged	11,148	10,580
% of shareholders who lodged proxies	6.78%	6.22%
Number of shareholders, corporate representatives and proxies who attended the AGM	325	276

**S M Bicknell**  
**Company Secretary**  
**6 May 2010**

These results will shortly be available on the Company's website  
[www.gsk.com](http://www.gsk.com)

Enquiries:

**GlaxoSmithKline Enquiries:**

UK Media enquiries: Philip Thomson (020) 8047 5502  
Claire Brough (020) 8047 5502  
Stephen Rea (020) 8047 5502  
Alexandra Harrison (020) 8047 5502  
Jo Revill (020) 8047 5502

US Media enquiries: Nancy Pekarek (919) 483 2839  
Mary Anne Rhyne (919) 483 2839  
Kevin Colgan (919) 483 2839  
Sarah Alspach (919) 483 2839

European Analyst/Investor enquiries: David Mawdsley (020) 8047 5564  
Sally Ferguson (020) 8047 5543  
Gary Davies (020) 8047 5503

US Analyst/ Investor enquiries: Tom Curry (215) 751 5419  
Jen Hill Baxter (215) 751 7002

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

**GlaxoSmithKline plc**  
(Registrant)

Date: May 06, 2010

By: VICTORIA WHYTE

-----

Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc